Results 11 to 20 of about 1,057,849 (262)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection

New Microbes and New Infections, 2020
Dornase alfa, the recombinant form of the human DNase I enzyme, breaks down neutrophil extracellular traps (NET) that include a vast amount of DNA fragments, histones, microbicidal proteins and oxidant enzymes released from necrotic neutrophils in the ...
H.K. Okur, K. Yalcin, C. Tastan, S. Demir, B. Yurtsever, G.S. Karakus, D.D. Kancagi, S. Abanuz, U. Seyis, R. Zengin, C. Hemsinlioglu, M. Kara, M.E. Yildiz, E. Deliceo, N. Birgen, N.B. Pelit, C. Cuhadaroglu, A.S. Kocagoz, E. Ovali   +18 more
doaj   +1 more source

Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application

Turkish Journal of Hematology, 2022
Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability and
Ebru Erdoğan, Koray Yalçın, Cansu Hemşinlioğlu, Aslıhan Sezgin, Utku Seyis, Derya Dilek Kancağı, Cihan Taştan, Bulut Yurtsever, Raife Dilek Turan, Didem Çakırsoy, Selen Abanuz, Gözde Sır Karakuş, Muhammer Elek, Hüseyin Saffet Beköz, Ali İhsan Gemici, Deniz Sargın, Mutlu Arat, Burhan Ferhanoğlu, Ebru Pekgüç, Serdar Örnek, Deram Büyüktaş, Nur Birgen, Siret Ratip, Ercüment Ovalı   +23 more
doaj   +1 more source

A TCR-based Chimeric Antigen Receptor

Scientific Reports, 2017
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection.
Even Walseng, Hakan Köksal, Ibrahim M. Sektioglu, Anne Fåne, Gjertrud Skorstad, Gunnar Kvalheim, Gustav Gaudernack, Else Marit Inderberg, Sébastien Wälchli   +8 more
doaj   +1 more source

Colorectal cysts as a validating tool for CAR therapy

BMC Biotechnology, 2020
Background Treatment of cancers has largely benefited from the development of immunotherapy. In particular, Chimeric Antigen Receptor (CAR) redirected T cells have demonstrated impressive efficacy against B-cell malignancies and continuous efforts are ...
Pierre Dillard, Maren Lie, Elizabeth Baken, Viola Hélène Lobert, Emmanuelle Benard, Hakan Köksal, Else Marit Inderberg, Sébastien Wälchli   +7 more
doaj   +1 more source

Imaging of cellular therapies

Advanced Drug Delivery Reviews, 2010
Cellular therapy promises to revolutionize medicine, by restoring tissue and organ function, and combating key disorders including cancer. As with all major developments, new tools must be introduced to allow optimization. For cell therapy, the key tool is in vivo imaging for real time assessment of parameters such as cell localization, numbers and ...
Srinivas, M., Aarntzen, E.H.J.G., Bulte, J.W., Oyen, W.J.G., Heerschap, A., de Vries, I.J.M., de Vries, I.J.M., de Vries, I.J.M., Figdor, C.G.   +8 more
openaire   +4 more sources

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation

HemaSphere, 2021
The nutritional status at diagnosis, as well as weight loss during chemotherapy, are important factors for morbidity and mortality in cancer patients. They might also influence outcomes in patients with acute myeloid leukemia (AML) receiving allogeneic ...
Dominic Brauer, Donata Backhaus, Rosmarie Pointner, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch   +7 more
doaj   +1 more source

Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice

Scientific Reports, 2021
The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization
Raife Dilek Turan, Cihan Tastan, Derya Dilek Kancagi, Bulut Yurtsever, Gozde Sir Karakus, Samed Ozer, Selen Abanuz, Didem Cakirsoy, Gamze Tumentemur, Sevda Demir, Utku Seyis, Recai Kuzay, Muhammer Elek, Miyase Ezgi Kocaoglu, Gurcan Ertop, Serap Arbak, Merve Acikel Elmas, Cansu Hemsinlioglu, Ozden Hatirnaz Ng, Sezer Akyoney, Ilayda Sahin, Cavit Kerem Kayhan, Fatma Tokat, Gurler Akpinar, Murat Kasap, Ayse Sesin Kocagoz, Ugur Ozbek, Dilek Telci, Fikrettin Sahin, Koray Yalcin, Siret Ratip, Umit Ince, Ercument Ovali   +32 more
doaj   +1 more source

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide

Leukemia Research Reports, 2023
Allogeneic stem cell transplant can have high morbidity and mortality in patients with myelofibrosis (MF) and multiple myeloma (MM). This phase 2 study used a novel myeloablative regimen of split-dose busulfan, fludarabine, and then post-transplant ...
Andrew D. Trunk, Sagar S. Patel, Josef T. Prchal, Douglas W. Sborov, Axel R. Zander, Catherine J. Lee   +5 more
doaj   +1 more source

Cellular therapy in Tuberculosis [PDF]

International Journal of Infectious Diseases, 2015
Cellular therapy now offer promise of potential adjunct therapeutic options for treatment of drug-resistant tuberculosis (TB). We review here the role of Mesenchymal stromal cells, (MSCs), as well as other immune effector cells in the therapy of infectious diseases with a focus on TB.
Shreemanta K. Parida, Rajhmun Madansein, Nalini Singh, Nesri Padayatchi, Iqbal Master, Kantharuben Naidu, Alimuddin Zumla, Markus Maeurer   +7 more
openaire   +3 more sources

High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources

Stem Cell Research & Therapy, 2018
Background Mesenchymal stromal cells (MSC) are a heterogeneous population of multipotent progenitors used in the clinic because of their immunomodulatory properties and their ability to differentiate into multiple mesodermal lineages.
Eliana Amati, Omar Perbellini, Gianluca Rotta, Martina Bernardi, Katia Chieregato, Sabrina Sella, Francesco Rodeghiero, Marco Ruggeri, Giuseppe Astori   +8 more
doaj   +1 more source